Hepatic Clinical Trials

227 recruitingLast updated: June 18, 2026

There are 227 actively recruiting hepatic clinical trials across 36 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 4, Phase 3, Early Phase 1. Top locations include San Antonio, Texas, United States, Shanghai, Shanghai Municipality, China, Orlando, Florida, United States. Updated daily from ClinicalTrials.gov.


Hepatic Trials at a Glance

227 actively recruiting trials for hepatic are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 2 with 62 trials, with the heaviest enrollment activity in San Antonio, Shanghai, and Orlando. Lead sponsors running hepatic studies include Fudan University, Mayo Clinic, and AstraZeneca.

Treatments under study

About Hepatic Clinical Trials

Looking for clinical trials for Hepatic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 227 trials

Recruiting
Phase 2

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Intrahepatic Cholangiocarcinoma (Icc)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University38 enrolled1 locationNCT06925516
Recruiting

QOL and Sarcopenia in Patients With Ascites

Ascites, MalignantAscites Hepatic
Abramson Cancer Center at Penn Medicine70 enrolled1 locationNCT05726747
Recruiting
Phase 1

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Liver DiseasesHepatic Insufficiency
Incyte Corporation16 enrolled4 locationsNCT07559474
Recruiting

ARPKD Database Study

Autosomal Recessive Polycystic Kidney DiseaseNephronophthisisCongenital Hepatic Fibrosis+7 more
Children's Hospital of Philadelphia200 enrolled6 locationsNCT01401998
Recruiting
Phase 1

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

Healthy VolunteersHepatic Impairment
Bristol-Myers Squibb24 enrolled3 locationsNCT07248839
Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal, CancerCholangiocarcinomaColorectal Neoplasms+10 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

HealthyHepatic Impairment
Boehringer Ingelheim32 enrolled3 locationsNCT07023354
Recruiting
Not Applicable

Erector Spinae Plane Block Versus Thoracic Epidural Analgesia for Open Liver Resection

Liver CancerLiver NeoplasmsHepatic Resection
Nguyen Toan Thang60 enrolled1 locationNCT07642336
Recruiting
Phase 2

Y-90 Treatment Response Using Transarterial Radioembolization

Liver CancerHepatocellular CarcinomaPrimary Liver Cancer+3 more
Thomas Jefferson University30 enrolled1 locationNCT07145801
Recruiting
Phase 1Phase 2

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

Biliary Tract CancerCholangiocarcinomaExtrahepatic Cholangiocarcinoma+2 more
Beijing Biotech30 enrolled1 locationNCT07641036
Recruiting
Phase 1

Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals24 enrolled5 locationsNCT07422610
Recruiting

Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study

Intrahepatic Cholangiocarcinoma (Icc)
Peking Union Medical College Hospital90 enrolled1 locationNCT07640048
Recruiting
Phase 1

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting
Phase 1

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

Severe Hepatic ImpairmentNormal Hepatic Function
Institut de Recherches Internationales Servier (I.R.I.S.)20 enrolled3 locationsNCT07250633
Recruiting
Phase 1

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

Hepatic Insufficiency
Eli Lilly and Company36 enrolled3 locationsNCT07401862
Recruiting
Phase 1

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Hepatic Impairment
AstraZeneca28 enrolled4 locationsNCT07546760
Recruiting
Phase 4

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

Progressive Familial Intrahepatic CholestasisAlagille Syndrome
Mirum Pharmaceuticals, Inc.230 enrolled15 locationsNCT07290257
Recruiting

Natural History of Noncirrhotic Portal Hypertension

Cystic FibrosisTurner SyndromeImmunologic Deficiency Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)400 enrolled1 locationNCT02417740
Recruiting
Not Applicable

Intravital Microscopy in Human Solid Tumors

Malignant Brain NeoplasmMalignant Solid NeoplasmAnatomic Stage IV Breast Cancer AJCC v8+20 more
Mayo Clinic85 enrolled1 locationNCT03823144